双成药业(002693) - 2017 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 103.90% to CNY 7,920,358.16 for the reporting period [7]. - Operating income for the period was CNY 84,116,539.95, representing a growth of 82.60% year-on-year [7]. - Basic earnings per share increased to CNY 0.02, a rise of 103.91% compared to the same period last year [7]. - The weighted average return on equity was 1.39%, up by 26.38% year-on-year [7]. - The company reported a net profit of CNY -9,620,656.85 for the year-to-date, a decrease of 95.69% compared to the same period last year [7]. - Revenue grew by 58.97% year-on-year, driven by changes in the sales model and the introduction of new products [16]. - The company expects a net profit of between 8 million and 12 million yuan for 2017, a turnaround from a loss of 388.41 million yuan in 2016 [23]. - The company reported a net loss of CNY 202,439,743.36, compared to a loss of CNY 192,819,086.51 in the previous period [33]. - The net profit for the current period was ¥10,455,254.12, compared to a net loss of ¥199,697,720.00 in the previous period, indicating a turnaround in profitability [49]. Assets and Liabilities - Total assets increased by 15.50% to CNY 1,346,176,504.99 compared to the end of the previous year [7]. - Total current assets increased to CNY 316,058,185.14 from CNY 151,413,821.89, representing a growth of 108.5% [30]. - Non-current assets totaled CNY 1,030,118,319.85, up from CNY 1,014,114,250.43, indicating a slight increase of 1.6% [31]. - Total liabilities decreased to CNY 598,513,714.20 from CNY 612,400,444.81, a reduction of 2.9% [32]. - Long-term borrowings increased to CNY 367,000,000.00 from CNY 297,000,000.00, showing a rise of 23.5% [32]. - Owner's equity totaled ¥600,106,442.43, up from ¥583,317,818.45, reflecting an increase of about 2.9% [39]. Cash Flow - The net cash flow from operating activities improved by 46.52% to CNY 24,582,057.50 [7]. - Cash received from operating activities increased by 69.00% year-on-year, mainly due to an increase in R&D-related receivables and product shipment guarantees [17]. - Operating cash inflow for the period was CNY 154,739,838.82, an increase of 22.6% compared to CNY 126,152,621.84 in the previous period [55]. - Net cash flow from operating activities was CNY 16,774,186.34, up from CNY 9,928,244.74, representing a 68.5% increase [55]. - Cash inflow from financing activities totaled CNY 534,760,000.00, a substantial increase from CNY 114,000,000.00 in the previous period [56]. - Net cash flow from financing activities was CNY 59,849,936.33, compared to CNY 9,391,884.17 in the previous period, marking a significant improvement [56]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 26,611 [11]. - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., held 34.45% of the shares [11]. - The company did not engage in any repurchase transactions during the reporting period [12]. Inventory and Receivables - Accounts receivable increased by 112.55% compared to the beginning of the year, mainly due to adjustments in the company's marketing model [15]. - Inventory increased by 326.59% compared to the beginning of the year, primarily due to increased stock of imported products by a subsidiary [15]. - Accounts receivable rose significantly to CNY 55,396,095.11 from CNY 26,063,021.11, marking an increase of 112.5% [30]. - Inventory surged to CNY 146,051,020.76 from CNY 34,236,580.42, reflecting a growth of 426.5% [30]. Expenses - Sales expenses increased by 115.40% year-on-year, attributed to the adjustments in the sales model [16]. - The company incurred sales expenses of ¥38,530,891.67, which is an increase of 82.0% from ¥21,169,054.67 in the previous period [39]. - The company reported a significant increase in sales expenses to ¥50,402,537.96 from ¥20,424,321.58 in the previous period, indicating higher marketing efforts [47].